RICHARD ZEKMAN, DO
Medical Oncology Physician · ROYAL OAK, MI
Individual Active NPI 1043426521
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 817 | 253,043 | $16,045,766 | $5,151,367 | $4,105,331 |
| 2023 | 779 | 281,777 | $13,503,933 | $4,346,258 | $3,459,670 |
| 2022 | 768 | 218,561 | $10,548,104 | $3,370,721 | $2,685,930 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | 51,750 | $1 | $1 |
| J9271 | Injection, pembrolizumab, 1 mg | 19,400 | $56 | $45 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 15,720 | $0 | $0 |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 12,672 | $26 | $21 |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 10,020 | $3 | $2 |
| J9267 | Injection, paclitaxel, 1 mg | 9,676 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 9,420 | $26 | $21 |
| J1453 | Injection, fosaprepitant, 1 mg | 8,250 | $0 | $0 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 7,501 | $8 | $6 |
| J9299 | Injection, nivolumab, 1 mg | 6,660 | $31 | $25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 3,371 | $0 | $0 |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | 2,230 | $40 | $32 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | 5101015788 | MI |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Michigan
- NPI 1811957756
- NPI 1417084799
- NPI 1992773741
- NPI 1629146154
- NPI 1548475387
- NPI 1578990727
- NPI 1609829001
- NPI 1417174699
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.